LOGIN  |  REGISTER
Astria Therapeutics
Assertio

Stryker reports third quarter 2024 operating results

October 29, 2024 | Last Trade: US$385.68 3.00 -0.77

Portage, Michigan, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Stryker reported operating results for the third quarter of 2024:

Third Quarter Results

  • Reported net sales increased 11.9% to $5.5 billion
  • Organic net sales increased 11.5%
  • Reported operating income margin of 19.7%
  • Adjusted operating income margin(1) increased 130 bps to 24.7%
  • Reported EPS increased 20.0% to $2.16
  • Adjusted EPS(1) increased 16.7% to $2.87
 Third Quarter Net Sales Growth Overview
 Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures Organic
MedSurg and Neurotechnology        12.8        %         (0.1)        %         12.9        %         0.2        %         12.7        %
Orthopaedics and Spine        10.7                  (0.1)                   10.8                  1.1                  9.7         
Total        11.9        %         (0.1)        %         12.0        %         0.5        %         11.5        %

"We delivered another strong quarter across our businesses and geographies and are on track to achieve our adjusted operating margin expansion goals," said Kevin A. Lobo, Chair and CEO. "Our product innovation and acquisitions will help to sustain our growth at the high end of MedTech."

Sales Analysis

Consolidated net sales of $5.5 billion increased 11.9% in the quarter and 12.0% in constant currency. Organic net sales increased 11.5% in the quarter including 10.3% from increased unit volume and 1.2% from higher prices.

MedSurg and Neurotechnology net sales of $3.2 billion increased 12.8% in the quarter and 12.9% in constant currency. Organic net sales increased 12.7% in the quarter including 11.0% from increased unit volume and 1.7% from higher prices.

Orthopaedics and Spine net sales of $2.3 billion increased 10.7% in the quarter and 10.8% in constant currency. Organic net sales increased 9.7% in the quarter including 9.3% from increased unit volume and 0.4% from higher prices.

Earnings Analysis

Reported net earnings of $834 million increased 20.5% in the quarter. Reported net earnings per diluted share of $2.16 increased 20.0% in the quarter. Reported gross profit margin and reported operating income margin were 64.0% and 19.7% in the quarter. Reported net earnings include certain items, such as charges for acquisition and integration-related activities, the amortization of purchased intangible assets, structural optimization and other special charges (including asset write-offs and impairments), costs to comply with certain medical device regulations, recall-related matters, regulatory and legal matters and tax matters. Excluding the aforementioned items, adjusted gross profit margin(1) was 64.5% in the quarter, and adjusted operating income margin(1) was 24.7% in the quarter. Adjusted net earnings(1) of $1.1 billion increased 17.3% in the quarter. Adjusted net earnings per diluted share(1) of $2.87 increased 16.7% in the quarter.

2024 Outlook

Based on our year-to-date performance, sustained demand for our capital products and healthy procedural volumes, we now expect full year 2024 organic net sales growth(2) to be in the range of 9.5% to 10.0% with a favorable pricing impact in the range of 0.5% to 1.0%. If foreign exchange rates hold near current levels, we anticipate a slightly unfavorable impact on full year net sales and now expect adjusted net earnings per diluted share(2) will be negatively impacted by approximately $0.10. This is reflected in our guidance. With a strong first nine months of the year and our strong sales momentum going into the fourth quarter, we now expect adjusted net earnings per diluted share(2) to be in the range of $12.00 to $12.10.

(1) A reconciliation of the non-GAAP financial measures: adjusted gross profit margin, adjusted operating income and adjusted operating income margin, adjusted net earnings and adjusted net earnings per diluted share, to the most directly comparable GAAP measures: gross profit margin, operating income and operating income margin, net earnings and net earnings per diluted share, and other important information accompanies this press release.

(2) We are unable to present a quantitative reconciliation of our expected net sales growth to expected organic net sales growth as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisitions and divestitures and the impact of foreign currency exchange rates. We are unable to present a quantitative reconciliation of our expected net earnings per diluted share to expected adjusted net earnings per diluted share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of structural optimization and other special charges, acquisition-related expenses and the outcome of certain regulatory, legal and tax matters. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Earnings.

Conference Call on Tuesday, October 29, 2024

As previously announced, we will host a conference call on Tuesday, October 29, 2024 at 4:30 p.m., Eastern Time, to discuss our operating results for the quarter ended September 30, 2024 and provide an operational update.

Please register for this conference call at: https://www.veracast.com/webcasts/stryker/events/SYK3Q24.cfm. After registering, a confirmation will be sent via email, including dial-in details and unique conference call access codes required for call entry. Registration is open throughout the live call. To ensure you are connected prior to the beginning of the call, we suggest registering a minimum of 15 minutes before the start of the call.

A simultaneous webcast of the call will be accessible via the Investor Relations page of our website at www.stryker.com. For those not planning to ask a question of management, we recommend listening via the webcast. Please allow 15 minutes to register, download and install any necessary software.

Following the conference call, a replay will be available on our website up to one year from the time of the earnings call.

Caution Concerning Forward-Looking Statements

This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions, or the anticipation thereof, that could adversely affect the level of demand for our products; geopolitical risks, including from international conflicts and elections in the United States and other countries, which could, among other things, lead to increased market volatility; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign currency exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect approval of new products by the United States Food and Drug Administration and foreign regulatory agencies; inflationary pressures; increased interest rates or interest rate volatility; supply chain disruptions; changes in labor markets; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to recall-related and other regulatory and quality matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; changes in tax laws and regulations; the impact of legislation to reform the healthcare system in the United States or other countries; costs to comply with medical device regulations; changes in financial markets; changes in our credit ratings; changes in the competitive environment; our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes; our ability to realize anticipated cost savings; potential negative impacts resulting from climate change or other environmental, social and governance and sustainability related matters; the impact on our operations and financial results of any public health emergency and any related policies and actions by governments or other third parties; and breaches or failures of our or our vendors' or customers' information technology systems or products, including by cyber-attack, data leakage, unauthorized access or theft. Additional information concerning these and other factors is contained in our filings with the United States Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com

For investor inquiries please contact:

Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it. 

For media inquiries please contact:

Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it. 

STRYKER CORPORATION
For the Three and Nine Months September 30
(Unaudited - Millions of Dollars, Except Per Share Amounts)
            
CONSOLIDATED STATEMENTS OF EARNINGS
        
 Three Months Nine Months
  2024           2023          % Change  2024           2023          % Change
Net sales$        5,494          $        4,909                  11.9        % $        16,159          $        14,683                  10.1        %
Cost of sales         1,977                   1,751                  12.9                   5,893                   5,328                  10.6         
Gross profit$        3,517          $        3,158                  11.4        % $        10,266          $        9,355                  9.7        %
% of sales         64.0        %          64.3        %            63.5        %          63.7        %  
Research, development and engineering expenses         377                   353                  6.8                   1,108                   1,038                  6.7         
Selling, general and administrative expenses         1,896                   1,710                  10.9                   5,583                   5,200                  7.4         
Amortization of intangible assets         159                   164                  (3.0)                  467                   486                  (3.9)        
Total operating expenses$        2,432          $        2,227                  9.2        % $        7,158          $        6,724                  6.5        %
Operating income$        1,085          $        931                  16.5        % $        3,108          $        2,631                  18.1        %
% of sales         19.7        %          19.0        %            19.2        %          17.9        %  
Other income (expense), net         (42)                  (62)                  (32.3)                  (144)                  (184)                 (21.7)        
Earnings before income taxes$        1,043          $        869                  20.0        % $        2,964          $        2,447                  21.1        %
Income taxes         209                   177                  18.1                   517                   425                  21.6         
Net earnings$        834          $        692                  20.5        % $        2,447          $        2,022                  21.0        %
Net earnings per share of common stock:           
Basic$        2.18          $        1.82                  19.8        % $        6.42          $        5.33                  20.5        %
Diluted$        2.16          $        1.80                  20.0        % $        6.35          $        5.27                  20.5        %
Weighted-average shares outstanding (in millions):           
Basic 381.1           379.8             380.9            379.5           
Diluted 385.6           384.0             385.4            383.7           

 

CONDENSED CONSOLIDATED BALANCE SHEETS
 September 30 December 31
  2024          2023        
Assets   
Cash and cash equivalents$        3,850         $        2,971        
Short-term investments         750                  —        
Marketable securities         84                  82        
Accounts receivable, net         3,736                  3,765        
Inventories         5,292                  4,843        
Prepaid expenses and other current assets         961                  857        
Total current assets$        14,673         $        12,518        
Property, plant and equipment, net         3,429                  3,215        
Goodwill and other intangibles, net         21,336                  19,836        
Noncurrent deferred income tax assets         1,562                  1,670        
Other noncurrent assets         2,833                  2,673        
Total assets$        43,833         $        39,912        
Liabilities and shareholders' equity   
Current liabilities$        7,669         $        7,921        
Long-term debt, excluding current maturities         13,325                  10,901        
Income taxes         368                  567        
Other noncurrent liabilities         2,322                  1,930        
Shareholders' equity         20,149                  18,593        
Total liabilities and shareholders' equity$        43,833         $        39,912        

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 Nine Months
  2024           2023         
Operating activities   
Net earnings$        2,447          $        2,022         
Depreciation         319                   292         
Amortization of intangible assets         467                   486         
Changes in operating assets, liabilities, income taxes payable and other, net         (922)                  (617)        
Net cash provided by operating activities$        2,311          $        2,183         
Investing activities   
Acquisitions, net of cash acquired$        (1,598)         $        (390)        
Purchases of property, plant and equipment         (489)                  (430)        
Other investing, net         (610)                  10         
Net cash used in investing activities$        (2,697)        $        (810)        
Financing activities   
Borrowings (payments) of debt, net$        2,378         $        (312)        
Payments of dividends         (914)                 (854)        
Other financing, net         (195)                 (142)        
Net cash provided by (used in) financing activities$        1,269         $        (1,308)        
Effect of exchange rate changes on cash and cash equivalents         (4)                 (49)        
Change in cash and cash equivalents$        879         $        16         

 

STRYKER CORPORATION
For the Three and Nine Months September 30
(Unaudited - Millions of Dollars)

 

SALES GROWTH ANALYSIS
 Three Months Nine Months
     Percentage Change     Percentage Change
  2024          2023         As ReportedConstant
Currency
  2024          2023         As ReportedConstant
Currency
Geographic:             
United States$        4,109         $        3,678                 11.7        %        11.7        % $        12,070         $        10,901                 10.7        %        10.7        %
International         1,385                  1,231                 12.5                 13.0                   4,089                  3,782                 8.1                 10.1         
Total$        5,494         $        4,909                 11.9        %        12.0        % $        16,159         $        14,683                 10.1        %        10.6        %
Segment:             
MedSurg and Neurotechnology$        3,224         $        2,859                 12.8        %        12.9        % $        9,340         $        8,409                 11.1        %        11.5        %
Orthopaedics and Spine         2,270                  2,050                 10.7                 10.8                   6,819                  6,274                 8.7                 9.2         
Total$        5,494         $        4,909                 11.9        %        12.0        % $        16,159         $        14,683                 10.1        %        10.6        %

 

SUPPLEMENTAL SALES GROWTH ANALYSIS
 Three Months
      United States International
   Percentage Change
  2024         2023        As ReportedConstant Currency As Reported As ReportedConstant Currency
MedSurg and Neurotechnology:           
Instruments$        679         $        620                 9.6        %        9.5        %         9.9        %         8.3        %        7.8        %
Endoscopy         837                  746                 12.2                 12.5                  11.3                  16.6                 18.1         
Medical         938                  798                 17.6                 17.7                  18.6                  12.7                 13.2         
Neurovascular         329                  311                 5.5                 5.9                  1.5                  8.1                 8.6         
Neuro Cranial         441                  384                 15.0                 15.0                  16.2                  9.4                 9.6         
 $        3,224         $        2,859                 12.8        %        12.9        %         13.3        %         10.9        %        11.4        %
Orthopaedics and Spine:           
Knees$        570         $        515                 10.6        %        10.7        %         8.4        %         17.1        %        17.4        %
Hips         420                  362                 15.9                 16.2                  10.9                  24.8                 25.3         
Trauma and Extremities         849                  752                 12.8                 12.6                  12.9                  12.6                 12.0         
Spine         304                  291                 4.6                 4.4                  3.5                  7.5                 6.8         
Other         127                  130                 (2.4)                0.1                  (0.6)                 (6.1)                1.3         
 $        2,270         $        2,050                 10.7        %        10.8        %         9.2        %         14.4        %        14.8        %
Total $        5,494         $        4,909                 11.9        %        12.0        %         11.7        %         12.5        %        13.0        %

 

 
 Nine Months
        United States International
     Percentage Change
  2024         2023        As ReportedConstant Currency As Reported As ReportedConstant Currency
MedSurg and Neurotechnology:           
Instruments$        2,044         $        1,808                 13.1        %        13.3        %         13.9        %         9.7        %        10.9        %
Endoscopy         2,383                  2,166                 10.0                 10.5                  10.2                  9.1                 11.6         
Medical         2,710                  2,417                 12.1                 12.3                  15.7                  (2.9)                (1.8)        
Neurovascular         966                  906                 6.6                 8.3                  2.2                  9.4                 12.4         
Neuro Cranial         1,237                  1,112                 11.3                 11.7                  11.4                  10.7                 12.9         
 $        9,340         $        8,409                 11.1        %        11.5        %         12.4        %         6.7        %        8.7        %
Orthopaedics and Spine:           
Knees$        1,760         $        1,643                 7.1        %        7.7        %         6.0        %         10.2        %        12.2        %
Hips         1,241                  1,130                 9.9                 10.9                  7.3                  14.4                 17.3         
Trauma and Extremities         2,511                  2,287                 9.8                 10.0                  10.8                  7.1                 7.8         
Spine         911                  871                 4.6                 4.8                  3.9                  6.5                 7.3         
Other         396                  343                 15.4                 17.8                  17.4                  11.2                 18.6         
 $        6,819         $        6,274                 8.7        %        9.2        %         8.3        %         9.7        %        11.6        %
Total $        16,159         $        14,683                 10.1        %        10.6        %         10.7        %         8.1        %        10.1        %

Notes: The three months 2024 had one more selling day than 2023. The nine months 2024 had the same number of selling days as 2023. Beginning in the first quarter 2024, a product line previously included in Instruments has been reclassified to Endoscopy to align with a change in our internal reporting structure. We have reflected this change in all historical periods presented.

SUPPLEMENTAL INFORMATION - RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP financial measures, including: percentage sales growth in constant currency; percentage organic sales growth; adjusted gross profit; adjusted selling, general and administrative expenses; adjusted research, development and engineering expenses; adjusted operating income; adjusted other income (expense), net; adjusted income taxes; adjusted effective income tax rate; adjusted net earnings; and adjusted net earnings per diluted share (Diluted EPS). We believe these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.

To measure percentage sales growth in constant currency, we remove the impact of changes in foreign currency exchange rates that affect the comparability and trend of sales. Percentage sales growth in constant currency is calculated by translating current and prior year results at the same foreign currency exchange rate. To measure percentage organic sales growth, we remove the impact of changes in foreign currency exchange rates, acquisitions and divestitures, which affect the comparability and trend of sales. Percentage organic sales growth is calculated by translating current year and prior year results at the same foreign currency exchange rates excluding the impact of acquisitions and divestitures. To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect the comparability of operating results and the trend of earnings. The income tax effect of each adjustment was determined based on the tax effect of the jurisdiction in which the related pre-tax adjustment was recorded. These adjustments are irregular in timing and may not be indicative of our past and future performance.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, selling, general and administrative expenses, research, development and engineering expenses, operating income, other income (expense), net, income taxes, effective income tax rate, net earnings and net earnings per diluted share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures below, provide a more complete understanding of our business. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

The following reconciles the non-GAAP financial measures discussed above with the most directly comparable GAAP financial measures. The weighted-average diluted shares outstanding used in the calculation of adjusted net earnings per diluted share are the same as those used in the calculation of reported net earnings per diluted share for the respective period.

STRYKER CORPORATION
For the Three and Nine Months September 30
(Unaudited - Millions of Dollars, Except Per Share Amounts)
          
Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures
Three Months 2024Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective
Tax Rate
Diluted EPS
Reported$        3,517         $        1,896         $        377         $        1,085         $        (42)        $        209         $        834                 20.0        %$        2.16        
Reported percent net sales         64.0        %         34.5        %         6.9        %         19.7        %        (0.8)        %nm         15.2        %  
Acquisition and integration-related costs:         
Inventory stepped-up to fair value         29                  —                  —                  29                  —                  7                  22                 0.2                  0.06        
Other acquisition and integration-related (a)         —                  (48)                 —                  48                  —                  11                  37                 0.3                  0.10        
Amortization of purchased intangible assets         —                  —                  —                  159                  —                  32                  127                 0.7                  0.32        
Structural optimization and other special charges (b)         (2)                 (26)                 —                  24                  —                  4                  20                 —                  0.05        
Medical device regulations (c)         —                  —                  (13)                 13                  —                  2                  11                 0.1                  0.03        
Recall-related matters (d)         —                  —                  —                  —                  —                  —                  —                 —                  —        
Regulatory and legal matters (e)         —                  1                  —                  (1)                 —                  —                  (1)                —                  —        
Tax matters (f)         —                  —                  —                  —                  —                  (57)                 57                 (5.5)                 0.15        
Adjusted$        3,544         $        1,823         $        364         $        1,357         $        (42)        $        208         $        1,107                 15.8        %$        2.87        
Adjusted percent net sales         64.5        %         33.2        %         6.6        %         24.7        %        (0.8)        %nm         20.1        %  

 

Three Months 2023Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective
Tax Rate
Diluted EPS
Reported$        3,158         $        1,710         $        353         $        931         $        (62)        $        177         $        692                 20.4        %$        1.80        
Reported percent net sales         64.3        %         34.8        %         7.2        %         19.0        %        (1.3)        %nm         14.1        %  
Acquisition and integration-related costs:         
Inventory stepped-up to fair value         —                  —                  —                  —                  —                  —                  —                 —                  —        
Other acquisition and integration-related (a)         —                  1                  —                  (1)                 —                  (28)                 27                 (3.1)                 0.07        
Amortization of purchased intangible assets         —                  —                  —                  164                  —                  36                  128                 1.6                  0.34        
Structural optimization and other special charges (b)         19                  (9)                 —                  28                  —                  7                  21                 0.3                  0.06        
Medical device regulations (c)         1                  —                  (18)                 19                  —                  4                  15                 0.2                  0.04        
Recall-related matters (d)         —                  (9)                 —                  9                  —                  2                  7                 0.1                  0.01        
Regulatory and legal matters (e)         —                  1                  —                  (1)                 —                  1                  (2)                0.1                  —        
Tax matters (f)         —                  —                  —                  —                  1                  (55)                 56                 (6.4)                 0.14        
Adjusted$        3,178         $        1,694         $        335         $        1,149         $        (61)        $        144         $        944                 13.2        %$        2.46        
Adjusted percent net sales         64.7        %         34.5        %         6.8        %         23.4        %        (1.2)        %nm         19.2        %  

nm - not meaningful

(a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:

 Three Months
  2024        2023       
Termination of sales relationships$        —         $        2         
Employee retention and workforce reductions         13                  3         
Changes in the fair value of contingent consideration         2                  (4)        
Manufacturing integration costs         1                  —         
Stock compensation payments upon a change in control         22                  —         
Other integration-related activities (e.g., deal costs and legal entity rationalization)         10                  (2)        
Adjustments to Operating Income $        48         $        (1)        
Charges for acquisition-related tax provisions         —                  (28)        
Other income taxes related to acquisition and integration-related costs         11                  —         
Adjustments to Income Taxes$        11         $        (28)        
Adjustments to Net Earnings$        37         $        27         

(b) Structural optimization and other special charges represent the costs associated with:

 Three Months
  2024         2023        
Employee retention and workforce reductions$        12          $        (5)        
Closure/transfer of manufacturing and other facilities (e.g., site closure, contract termination and redundant employee costs)         2                   12         
Product line exits (e.g., inventory, long-lived asset and specifically-identified intangible asset write-offs)         4                   7         
Certain long-lived and intangible asset write-offs and impairments         12                   9         
Termination of sales relationships in certain countries         6                   —         
Other charges         (12)                  5         
Adjustments to Operating Income $        24          $        28         
Adjustments to Income Taxes$        4          $        7         
Adjustments to Net Earnings$        20          $        21         

(c) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union.
(d) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain recall-related matters.
(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.
(f) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:

 Three Months
  2024   2023 
Adjustments related to the transfer of certain intellectual properties between tax jurisdictions$        (47)   $        (44)  
Other tax matters (10)    (11)  
Adjustments to Income Taxes$        (57)   $        (55)  
Charges / (benefits) for certain tax audit settlements —      1   
Adjustments to Other Income (Expense), Net$             $        1   
Adjustments to Net Earnings$        57    $        56   

 

Nine Months 2024Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective
Tax Rate
Diluted EPS
Reported$        10,266         $        5,583         $        1,108         $        3,108         $        (144        )$        517         $        2,447                 17.4        %$        6.35        
Reported percent net sales         63.5        %         34.6        %         6.9        %         19.2        %        (0.9)        %nm         15.1        %  
Acquisition and integration-related costs:         
Inventory stepped-up to fair value         38                  —                  —                  38                  —                  9                  29                 0.3                  0.08        
Other acquisition and integration-related (a)         —                  (49)                  —                  49                  —                  14                  35                 0.2                  0.09        
Amortization of purchased intangible assets         —                  —                  —                  467                  —                  96                  371                 1.0                  0.96        
Structural optimization and other special charges (b)         41                  (72)                 —                  113                  —                  24                  89                 0.2                  0.23        
Medical device regulations (c)         5                  —                  (36)                 41                  —                  9                  32                 0.1                  0.08        
Recall-related matters (d)         11                  (11)                 —                  22                  —                  5                  17                 0.1                  0.04        
Regulatory and legal matters (e)         —                  1                  —                  (1)                 —                  —                  (1)                —                  —        
Tax matters (f)         —                  —                  —                  —                  (1)                 (136)                 135                 (4.7)                 0.35        
Adjusted$        10,361         $        5,452         $        1,072         $        3,837         $        (145)        $        538         $        3,154                 14.6        %$        8.18        
Adjusted percent net sales         64.1        %         33.7        %         6.6        %         23.7        %        (0.9)        %nm         19.5        %  

 

Nine Months 2023Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective
Tax Rate
Diluted EPS
Reported$        9,355         $        5,200         $        1,038         $        2,631         $        (184)        $        425         $        2,022                 17.4        %$        5.27        
Reported percent net sales         63.7        %         35.4        %         7.1        %         17.9        %        (1.3)        %nm         13.8        %  
Acquisition and integration-related costs:         
Inventory stepped-up to fair value         —                  —                  —                  —                  —                  —                  —                 —                  —        
Other acquisition and integration-related (a)         —                  (7)                 —                  7                  —                  (25)                 32                 (1.0)                 0.08        
Amortization of purchased intangible assets         —                  —                  —                  486                  —                  104                  382                 1.5                  1.00        
Structural optimization and other special charges (b)         30                  (112)                 —                  142                  —                  32                  110                 0.5                  0.29        
Medical device regulations (c)         1                  —                  (73)                 74                  —                  17                  57                 0.3                  0.15        
Recall-related matters (d)         —                  (12)                 —                  12                  —                  3                  9                 —                  0.02        
Regulatory and legal matters (e)         —                  (19)                 —                  19                  —                  4                  15                 —                  0.04        
Tax matters (f)         —                  —                  —                  —                  (8)                 (121)                 113                 (4.9)                 0.29        
Adjusted$        9,386         $        5,050         $        965         $        3,371         $        (192)        $        439         $        2,740                 13.8        %$        7.14        
Adjusted percent net sales         63.9        %         34.4        %         6.6        %         23.0        %        (1.3)        %nm         18.7        %  

(a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:

 Nine Months
  2024         2023      
Termination of sales relationships$        3          $        2         
Employee retention and workforce reductions         17                   3         
Changes in the fair value of contingent consideration         (12)                  (7)        
Manufacturing integration costs         2                   2         
Stock compensation payments upon a change in control         22                   —         
Other integration-related activities (e.g., deal costs and legal entity rationalization)         17                   7         
Adjustments to Operating Income $        49          $        7         
Charges for acquisition-related tax provisions         —                   (28)        
Other income taxes related to acquisition and integration-related costs         14                   3         
Adjustments to Income Taxes$        14          $        (25)        
Adjustments to Net Earnings$        35          $        32         

(b) Structural optimization and other special charges represent the costs associated with:

 Nine Months
  2024        2023      
Employee retention and workforce reductions$        14         $        63        
Closure/transfer of manufacturing and other facilities (e.g., site closure, contract termination and redundant employee costs)         18                  36        
Product line exits (e.g., inventory, long-lived asset and specifically-identified intangible asset write-offs)         19                  16        
Certain long-lived and intangible asset write-offs and impairments         22                  12        
Termination of sales relationships in certain countries         7                  —        
Other charges         33                  15        
Adjustments to Operating Income $        113         $        142        
Adjustments to Income Taxes$        24         $        32        
Adjustments to Net Earnings$        89         $        110        

(c) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union.
(d) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain recall-related matters.
(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.
(f) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:

 Nine Months
  2024   2023 
Adjustments related to the transfer of certain intellectual properties between tax jurisdictions$        (141)   $        (138)  
Certain tax audit settlements         (2)     24   
Other tax matters         7      (7)  
Adjustments to Income Taxes$        (136)    $        (121)  
Charges / (benefits) for certain tax audit settlements         (1)     (9)  
Other tax related adjustments         —      1   
Adjustments to Other Income (Expense), Net$        (1)    $        (8)  
Adjustments to Net Earnings$        135     $        113   
    

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB